Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21527477 | 0.83 | ALDH1A1 (0.34) | MAPTCREBBP | |
| SCHEMBL20786627 | 0.77 | DGAT1 (0.30) | — | |
| SCHEMBL21527513 | 0.72 | TRPA1 (0.61) | TRPA1 | |
| SCHEMBL20182610 | 0.71 | MAPT (0.34) | TRPA1MAPTRECQLGABRA5 | |
| SCHEMBL19399934 | 0.70 | TRPA1 (0.63) | TRPA1 | |
| SCHEMBL21609700 | 0.70 | MAPT (0.40) | TRPA1MAPTRECQLP2RX3GABRA5 | |
| SCHEMBL21527507 | 0.70 | BRD4 (0.35) | RECQLBRD4CREBBP | |
| SCHEMBL21609659 | 0.69 | TRPA1 (0.62) | TRPA1 | |
| SCHEMBL17609505 | 0.69 | TRPA1 (0.66) | TRPA1 | |
| SCHEMBL20785620 | 0.68 | TRPA1 (0.65) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | TRPA1 2/4885MAPT 2292/4885RECQL 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.